close

Mergers and Acquisitions

Date: 2016-11-30

Type of information: Company acquisition

Acquired company: G7 Therapeutics (Switzerland)

Acquiring company: Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan)

Amount: CHF 12 million

Terms:

* On November 30, 2016, Heptares Therapeutics announced it has signed a share purchase agreement that will allow the acquisition of 100% in G7 Therapeutics, a privately held drug discovery and development company based in Switzerland, for CHF 12 million cash.  Upon completion of the acquisition, G7 Therapeutics will become a wholly owned Zurich-based subsidiary of Heptares and will be renamed Heptares Zurich. The subsidiary will be led by Fiona Marshall, Chief Scientific Officer at Heptares and at Sosei.


Details:

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares’ proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, the company is building a pipeline of new small molecules and biologics with the potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. G7 Therapeutics' acquisition broadens and strengthens Heptares’ intellectual property and platform for structure-based drug design and development focused on GPCRs. The combination of Heptares’ and G7 Therapeutics’ platforms is anticipated to increase Heptares’ R&D productivity in terms of generating stabilised GPCRs and high quality GPCR structures that underpin discovery efforts for its proprietary pipeline and for partners.
G7 Therapeutics has developed proprietary approaches for stabilising GPCRs (called SaBRE and CHESS), which are different and highly complementary to the StaR® platform developed by Heptares. SaBRE and CHESS are of particular use where the target GPCR is present in very low numbers on cells and the methods are particularly powerful in the numbers of stabilizing mutations that can be identified in a short time for rapidly generating high quality GPCRs.

Related:

Technology - Services

Is general: Yes